According to DelveInsight's estimates, the sickle cell disease market size in the 7MM is expected to show positive growth, during the forecast period (2023-2032), mainly attributed to the increasing
CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia Achieves 50% Enrollment in CAHmelia-204 and Approaches 75% Enrollment in CAHmelia-203
Enrollment in P.O.W.E.R. Study for Polycystic. | May 15, 2023
'It is not negotiation at all. It is price setting,' says Pfizer CEO Albert Bourla, referring to the Biden administration’s signature drug pricing reform, part of the Inflation Reduction Act